共 198 条
[1]
Jemal A(2008)Cancer statistics, 2008 CA Cancer J Clin 58 71-96
[2]
Siegel R(2007)Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 581-592
[3]
Ward E(2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-2342
[4]
Hao Y(2006)A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200 Ann Oncol 17 1399-1403
[5]
Xu J(2007)Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539-1544
[6]
Murray T(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-2019
[7]
Ferlay J(2008)Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 5326-5334
[8]
Autier P(2009)Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann Oncol 20 1842-1847
[9]
Boniol M(2005)Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale J Clin Oncol 23 4866-4875
[10]
Heanue M(2000)Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938-2947